当前位置: 首页 > 新闻 > 信息荟萃
编号:144515
Axonyx公司治疗 Alzheimer病的药物在Ii期试验
http://www.100md.com 2001年11月1日 好医生

     NEW YORK (Reuters Health) - Axonyx Inc. on Tuesday reported positive phase II results for its lead drug candidate Phenserine (N-phenylcarbamoyl eseroline) in treating Alzheimer's disease.

    Phenserine, an acetylcholinesterase inhibitor, was tested in a double-blind, placebo-controlled trial of 72 patients with mild-to-moderate Alzheimer's disease.

    Axonyx said that the trial results suggest the drug may have a better side-effect profile than currently-marketed acetylcholinesterase inhibitors. The company stressed that the incidence of nausea and vomiting, which it called the most debilitating adverse event associated with the drug class, was only about 8.5% in the study.

    Marketed acetylcholinesterase inhibitors include Novartis' Exelon (rivastigmine tartrate) and Pfizer's Aricept (donepezil).

    The Phenserine study was not designed to measure efficacy. However, results indicated that the drug appeared to improve memory and cognition over the 12-week treatment period, according to Axonyx.

    In a conference call on Monday, Axonyx CEO Dr. Marvin Hausman said that the company would meet with the US Food and Drug Administration over the next few months to review phase III protocols. One issue that is likely to arise is whether the agency will allow a change in subjects' scores on the CANTAB cognition test--which was used in the phase II study--to serve as a primary endpoint, company officials noted.

    The phase III trial could involve higher dosages than those evaluated in phase II in an attempt to maximize efficacy, they added.

    Hausman said that Axonyx is considering a number of options to fund the continuing development of Phenserine, including entering a development partnership, out-licensing the drug and raising additional capital. The firm licensed exclusive worldwide rights to Phenserine from the National Institutes of Health.
    信息仅供参考,不构成任何之建议、推荐或指引。文章版权属于原著作权人,若您认为此文不宜被收录供大家免费阅读,请邮件或电话通知我们,我们收到通知后,会立即将您的作品从本网站删除。

   微信文章  关注百拇  评论几句  搜索更多